Education

The hub for all your learning resources.

Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.

60 minutes to Watch

In this webinar, Dr Raewyn Fisher discusses the range of disease-modifying therapies that have improved heart failure outcomes, and provides reassurance around the funding changes to cilazapril.

Contributor
Dr Raewyn Fisher
24 August 2021

When initiating either empagliflozin or dulaglutide, the newly funded second-line type 2 diabetes agents,choice is based primarily on predominant comorbidities, clinical features and tolerability.

Administration route is an additional factor; dulaglutide is a once-weekly, subcutaneous injection and empagliflozin is a daily tablet. Patient factors are also important, and the contraindications and adverse effects profiles differ. 

Read the HAH Bulletin to find out more.

Contributor
He Ako Hiringa
17 August 2021
4 minutes to Read + 15 minutes to Explore

Biological medicines are already used in Aotearoa New Zealand and with more being developed internationally, it’s important that health professionals feel comfortable prescribing, dispensing, and supporting patients to use them.

As an introduction, we’ve highlighted five key aspects of these medicines in an article and a series of short animated videos.

Contributor
He Ako Hiringa
11 August 2021

Prescribers wanting to block angiotensin II effects can consider the remaining funded ACE inhibitors or angiotensin II receptor blockers. ACE inhibitors and ARBs are similarly effective for hypertension, chronic renal disease and diabetic nephropathy, but ARBs are better tolerated.2 ACE inhibitors are preferred over ARBs first-line for heart failure and post myocardial infarction.2

Read the HAH Bulletin to find out more.

Contributor
He Ako Hiringa
19 July 2021
1 minute to Read

Pharmac has identified five key drivers of medicine access equity in New Zealand. Read on to learn about the drivers and how you can implement them in your place of work. 

13 July 2021
7 minutes to Read

Dulaglutide, a once-weekly injectable medicine, will soon be available for second-line treatment of type 2 diabetes. As most people with type 2 diabetes will require an injectable therapy at some stage, it is important to build acceptability early in the patient journey.

Contributor
Louise Roche Farmer
29 June 2021
2 minutes to Delve

Compliance, adherence, concordance – confused?

Whatever terminology is used, studies show that differences in health literacy, medicines access, attitudes to health and prescriber perceptions, may contribute to sub-optimal use of medicines and poor health outcomes.1

Read the HAH Bulletin to find out about strategies to improve medicine access/supply.

Contributor
He Ako Hiringa
24 May 2021
2 minutes to Read + 43 minutes to Explore

Focusing on the experiences of older Māori in primary care, this course comprises four short videos, an independent reflection, downloadable posters and additional resources.

The course is endorsed by RNZCGP and CNA(NZ) and meets PCNZ recertification requirements. Reflection templates are included for you to complete.

Contributor
Jo Hikaka
18 May 2021

This Quality Improvement Activity enables you to review the glycaemic management of your type 2 diabetes patients and identify those who may benefit from initiation or intensification of blood glucose lowering medicines.

Good glycaemic control has a clear benefit on microvascular outcomes and if started early enough, on long-term macrovascular outcomes of coronary artery disease, stroke and peripheral vascular disease.

Contributor
He Ako Hiringa
3 May 2021